Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
Part of paid clinical trials in Chapel Hill, North Carolina.
- Sponsor
- University of North Carolina, Chapel Hill
- Study ID
- NCT00807482
- Status
- Recruiting
Conditions
- Kartagener Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Study Details
The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect ciliary function and cause primary ciliary dyskinesia (PCD), which results in life-shortening lung disease. The long-term goal of this project is to develop better understanding of the underlying genetic variability that adversely modifies ciliary function, and predisposes to common airway diseases, such as asthma and chronic obstructive pulmonary disease.
Key Dates
- Start date
- Jan 31, 2004
- Status verified
- May 2025
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 1,800 participants (estimated)
Arms
- Arm: 1People who have been definitively diagnosed with primary ciliary dyskinesia (PCD).
Primary Outcome Measure
This is not an interventional study [ Time Frame: This is not an interventional study ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 |
Find similar trials in Chapel Hill, NC
By research site